Global and Indian manufacturing companies with strong brands and reputations have suffered more than a few damaging quality related shocks in recent years. Yet, companies continue to underestimate the risk and costs associated with poor quality. Real costs are often higher than is commonly believed. Quality processes are important in every industry, but more so in pharmaceuticals where scrutiny and standards are high. The problems are rarely accidental, and a deep-rooted transformation approach is essential to address them. In the last few years, like their global peers, Indian ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?